Global inhaled nitric oxide delivery systems market is expected to foresee significant growth during the forecast period. North America to witness the fastest growth
- Vikas Kumar
- February 18, 2022
- HEALTHCARE, NEWS
- inhaled nitric oxide delivery systems market Growth, inhaled nitric oxide delivery systems market news, inhaled nitric oxide delivery systems market share, inhaled nitric oxide delivery systems market Size, inhaled nitric oxide delivery systems market Trend
- 0 Comments
Global inhaled nitric oxide delivery systems market is expected to grow significantly by 2027 expanding at a reasonable CAGR of around 6% during the forecast period (2021-2027). Inhaled Nitric Oxide is a minimally invasive therapy that is used for the treatment of conditions associated with reversible pulmonary vasoconstriction and pulmonary hypertension. It is a selective pulmonary Vaso-dilator, which reduces pressures in the pulmonary artery and improves arterial oxygenation in infants and adults with respiratory failures.
For a detailed analysis of the inhaled nitric oxide delivery systems browse through https://univdatos.com/report/inhaled-nitric-oxide-delivery-systems-market/
The global inhaled nitric oxide delivery systems market is anticipated to witness an uptick on account of the rapidly growing geriatric population that is more prone to various lung diseases across the globe. According to the United Nations, the global population aged 60 years or over was numbered at 962 million in 2017 and is expected to reach nearly 2.1 billion by 2050. Furthermore, the rising preference for minimally invasive therapy and increased focus of many industry players to launch new and innovative products coupled with expedited FDA approvals are also some of the prominent factors contributing to the growth of inhaled nitric oxide delivery system market globally. For example, in 2020, the U.S. FDA approved the inhaled nitric oxide delivery systems manufactured by Bellerophon Therapeutics for the management of respiratory failure in COVID-19 patients.
Based on type, the market is segmented into paediatrics and adults. The paediatrics segment grabbed an XX% share of the global inhaled nitric oxide delivery systems market and will witness a considerable CAGR of XX% during the forecast period (2021-2027F). This is because of the growing prevalence of neonatal diseases and the increased adoption of inhaled nitric oxide as an effective treatment for diseases including Hypoxic Respiratory Failure.
For a detailed analysis of the types of inhaled nitric oxide delivery systems browse through https://univdatos.com/get-a-free-sample-form-php/?product_id=17462
Based on the application, the global inhaled nitric oxide delivery systems market is segmented into hypoxic respiratory failure (HRF), acute hypoxemic respiratory failure, chronic obstructive pulmonary disease, and others. The hypoxic respiratory failure occupied a substantial share and is expected to grow at a CAGR of XX% during the forecast period 2021-2027 owing to the growing prevalence of HRF, cost-effectiveness, and high efficacy of inhaled nitric oxide therapy.
Request for Sample of the report browse through https://univdatos.com/get-a-free-sample-form-php/?product_id=17462
Additionally, the report provides detailed report also provides insights into the global inhaled nitric oxide delivery systems market according to the regions such as North America (United States, Canada, and the Rest of North America), Europe (Germany, France, Italy, Spain, United Kingdom, and Rest of Europe), Asia-Pacific (China, India, Australia, Japan, and Rest of APAC), Rest of World has been conducted. Asia-Pacific dominated the market and generated revenue of USD xx billion in 2020 owing to the growing prevalence of repiratory diseases. However, North America is expected to witness the fastest growth in the upcoming years.
Mallinckrodt Pharmaceuticals, Getinge, Vero Biotech, LINDE, Beyond Air, Air Liquide Healthcare, Circassia Pharmaceuticals, NU MED, Bellerophon Therapeutics, Praxair Technology Inc., are some of the key players operating in the global inhaled nitric oxide delivery systems market. Several M&As along with partnerships have been undertaken by these players to develop a new and advanced inhaled nitric oxide delivery systems.
Global Inhaled Nitric Oxide Delivery Systems Market Segmentation
Market Insight, by Type
Market Insight, by Application
- Hypoxic Respiratory Failure (HRF)
- Acute Hypoxemic Respiratory Failure (AHRF)
- Chronic Obstructive Pulmonary Disease (COPD)
Market Insight, by Product Type
Market Insight, by End-Users
- Ambulatory Centers
Market Insight, by Region
- North America
- United States
- Rest of North America
- United Kingdom
- Rest of Europe
- Rest of Asia-Pacific
- Rest of World
Top Company Profiles
- Mallinckrodt Pharmaceuticals
- Vero Biotech
- Beyond Air
- Air Liquide Healthcare
- Circassia Pharmaceuticals
- NU MED
- Bellerophon Therapeutics
- Praxair Technology Inc.